Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Crown Bioscience Launches CrownSyn™, an Innovative Bioinformatics Solution that Simplifies the Characterization of Two-Drug Combination Studies


Posted on: 09 Jan 18

SAN DIEGO, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a novel bioinformatics tool that makes it easy for researchers to understand drug combination effects. CrownSyn™ is now available as an add-on feature to all two-drug combinatorial studies conducted by Crown Bioscience.

Combination therapies can improve efficacy, overcome drug resistance and decrease toxicity. They are an increasingly important treatment modality for several complex conditions including cancer, inflammatory, autoimmune, neurodegenerative, cardiovascular and metabolic diseases. To help our clients evaluate the efficacy of two-drug combinations, Crown Bioscience’s expert team of bioinformaticians developed CrownSyn™. CrownSyn™ is a tool that helps clients visualize and characterize combination effects as synergistic, antagonistic, and additive as well as determine optimal doses for further safety and efficacy studies. CrownSyn™ makes well-validated computational methods from published papers readily available to biologists.

CrownSyn™ is compatible with most experimental designs and provides dose-response curve graphs, combination index graphs, inhibition heat maps for concentration combinations, 2-D contour maps and 3D response surface plots. This assortment of graphical outputs makes it easy for clients to select efficacious combinations to advance their preclinical development programs.

“Combination therapies are a cornerstone for the treatment of complex diseases like resistant and metastatic cancers, cardiovascular, metabolic and inflammatory diseases,” said Laurie Heilmann, Crown Bioscience’s Chief Business Officer. “CrownSyn™ is CrownBio’s latest contribution to help our clients progress innovative drug development programs aimed at treating these complicated conditions with combination therapies.”

About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. 
marketing@crownbio.com

GlobeNewswire
globenewswire.com

Last updated on: 10/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.